{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"15.2","value":"1.4"},{"groupId":"OG001","lowerLimit":"1.2","upperLimit":"2.8","value":"1.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"TTR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"20.1","value":"1.4"},{"groupId":"OG001","lowerLimit":"1.1","upperLimit":"2.8","value":"1.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Intracranial TTR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Time to tumor response (TTR) was defined as the time from the first dose of study treatment to the first documentation of objective tumor response (CR or PR). For participants whose objective response proceeded from PR to CR, the onset of PR was taken as the onset of response. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \\<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. TTR was only calculated for the subgroup of participants with a confirmed objective tumor response. Intracranial TTR was only calculated for participants with confirmed intracranial objective response. Results presented here were based on independent central review.","dispersionType":"Full Range","groups":[{"description":"This reporting arm includes all Phase 1 participants who had documented ALK rearrangement.","id":"OG000","title":"ALK Positive Population (Phase 1)"},{"description":"This reporting arm includes all Phase 1 participants who had documented ROS1 rearrangement.","id":"OG001","title":"ROS1 Positive Population (Phase 1)"}],"paramType":"MEDIAN","populationDescription":"TTR analysis set included all ITT participants who had confirmed objective response; intracranial TTR analysis set included all ITT participants who had CNS metastases and achieved confirmed intracranial objective response.","reportingStatus":"POSTED","timeFrame":"From start of study treatment to the first documentation of objective tumor response (CR or PR) (maximum of 8 years approximately)","title":"Time to Tumor Response (TTR) and Intracranial TTR (Phase 1)","type":"SECONDARY","unitOfMeasure":"Months"}